| Year |
Citation |
Score |
| 2023 |
Rowland RJ, Heath R, Maskell D, Thompson RF, Ranson NA, Blaza JN, Endicott JA, Noble MEM, Salamina M. Cryo-EM structure of SKP1-SKP2-CKS1 in complex with CDK2-cyclin A-p27KIP1. Scientific Reports. 13: 10718. PMID 37400515 DOI: 10.1038/s41598-023-37609-9 |
0.319 |
|
| 2022 |
Miller DC, Reuillon T, Molyneux L, Blackburn T, Cook SJ, Edwards N, Endicott JA, Golding BT, Griffin RJ, Hardcastle I, Harnor SJ, Heptinstall A, Lochhead P, Martin MP, Martin NC, ... ... Noble MEM, et al. Parallel Optimization of Potency and Pharmacokinetics Leading to the Discovery of a Pyrrole Carboxamide ERK5 Kinase Domain Inhibitor. Journal of Medicinal Chemistry. PMID 35468293 DOI: 10.1021/acs.jmedchem.1c01756 |
0.306 |
|
| 2021 |
Al-Khawaldeh I, Al Yasiri MJ, Aldred GG, Basmadjian C, Bordoni C, Harnor SJ, Heptinstall AB, Hobson SJ, Jennings CE, Khalifa S, Lebraud H, Martin MP, Miller DC, Shrives HJ, de Souza JV, ... ... Noble MEM, et al. An Alkynylpyrimidine-Based Covalent Inhibitor That Targets a Unique Cysteine in NF-κB-Inducing Kinase. Journal of Medicinal Chemistry. PMID 34212719 DOI: 10.1021/acs.jmedchem.0c01249 |
0.329 |
|
| 2020 |
Lochhead PA, Tucker JA, Tatum NJ, Wang J, Oxley D, Kidger AM, Johnson VP, Cassidy MA, Gray NS, Noble MEM, Cook SJ. Paradoxical activation of the protein kinase-transcription factor ERK5 by ERK5 kinase inhibitors. Nature Communications. 11: 1383. PMID 32170057 DOI: 10.1038/S41467-020-15031-3 |
0.371 |
|
| 2018 |
Wood DJ, Korolchuk S, Tatum NJ, Wang LZ, Endicott JA, Noble MEM, Martin MP. Differences in the Conformational Energy Landscape of CDK1 and CDK2 Suggest a Mechanism for Achieving Selective CDK Inhibition. Cell Chemical Biology. PMID 30472117 DOI: 10.1016/J.Chembiol.2018.10.015 |
0.353 |
|
| 2018 |
Fazal L, Ahn M, Bevan L, Buck I, Castro J, Chessari G, Cons B, Hearn K, Howard S, Johnson C, Reeks J, Tamanini E, Thompson N, Walton H, Williams P, ... ... Noble M, et al. Abstract 1652: Development of a potent class of small molecule inhibitors of the MDM2-p53 protein-protein interaction Cancer Research. 78: 1652-1652. DOI: 10.1158/1538-7445.Am2018-1652 |
0.325 |
|
| 2017 |
Martin MP, Endicott JA, Noble MEM. Structure-based discovery of cyclin-dependent protein kinase inhibitors. Essays in Biochemistry. 61: 439-452. PMID 29118092 DOI: 10.1042/EBC20170040 |
0.343 |
|
| 2017 |
Hallett ST, Pastok MW, Morgan RML, Wittner A, Blundell KLIM, Felletar I, Wedge SR, Prodromou C, Noble MEM, Pearl LH, Endicott JA. Differential Regulation of G1 CDK Complexes by the Hsp90-Cdc37 Chaperone System. Cell Reports. 21: 1386-1398. PMID 29091774 DOI: 10.1016/j.celrep.2017.10.042 |
0.313 |
|
| 2017 |
Whittaker SR, Barlow C, Martin MP, Mancusi C, Wagner S, Self A, Barrie E, Te Poele R, Sharp S, Brown N, Wilson S, Jackson W, Fischer PM, Clarke PA, Walton MI, ... ... Noble M, et al. Molecular profiling and combinatorial activity of CCT068127: A potent CDK2 and CDK9 inhibitor. Molecular Oncology. PMID 29063678 DOI: 10.1002/1878-0261.12148 |
0.436 |
|
| 2016 |
Coxon CR, Anscombe E, Harnor SJ, Martin MP, Carbain BJ, Golding BT, Hardcastle IR, Harlow LK, Korolchuk S, Matheson CJ, Newell DR, Noble ME, Sivaprakasam M, Tudhope SJ, Turner DM, et al. Cyclin-Dependent Kinase (CDK) Inhibitors; Structure-Activity Relationships and Insights into the CDK-2 Selectivity of 6-Substituted 2-Arylaminopurines. Journal of Medicinal Chemistry. PMID 28005359 DOI: 10.1021/Acs.Jmedchem.6B01254 |
0.386 |
|
| 2015 |
Anscombe E, Meschini E, Mora-Vidal R, Martin MP, Staunton D, Geitmann M, Danielson UH, Stanley WA, Wang LZ, Reuillon T, Golding BT, Cano C, Newell DR, Noble ME, Wedge SR, et al. Identification and Characterization of an Irreversible Inhibitor of CDK2. Chemistry & Biology. PMID 26320860 DOI: 10.1016/J.Chembiol.2015.07.018 |
0.374 |
|
| 2015 |
Brown NR, Korolchuk S, Martin MP, Stanley WA, Moukhametzianov R, Noble ME, Endicott JA. CDK1 structures reveal conserved and unique features of the essential cell cycle CDK. Nature Communications. 6: 6769. PMID 25864384 DOI: 10.1038/ncomms7769 |
0.366 |
|
| 2013 |
Endicott JA, Noble ME. Structural characterization of the cyclin-dependent protein kinase family. Biochemical Society Transactions. 41: 1008-16. PMID 23863171 DOI: 10.1042/BST20130097 |
0.369 |
|
| 2013 |
Shao H, Shi S, Huang S, Hole AJ, Abbas AY, Baumli S, Liu X, Lam F, Foley DW, Fischer PM, Noble M, Endicott JA, Pepper C, Wang S. Substituted 4-(thiazol-5-yl)-2-(phenylamino)pyrimidines are highly active CDK9 inhibitors: synthesis, X-ray crystal structures, structure-activity relationship, and anticancer activities. Journal of Medicinal Chemistry. 56: 640-59. PMID 23301767 DOI: 10.1021/Jm301475F |
0.409 |
|
| 2013 |
Hole AJ, Baumli S, Shao H, Shi S, Huang S, Pepper C, Fischer PM, Wang S, Endicott JA, Noble ME. Comparative structural and functional studies of 4-(thiazol-5-yl)-2-(phenylamino)pyrimidine-5-carbonitrile CDK9 inhibitors suggest the basis for isotype selectivity. Journal of Medicinal Chemistry. 56: 660-70. PMID 23252711 DOI: 10.1021/Jm301495V |
0.352 |
|
| 2013 |
Shao H, Shi S, Huang S, Hole A, Abbas AY, Baumli S, Liu X, Lam F, Foley DW, Fischer PM, Noble M, Endicott JA, Pepper C, Wang S. Substituted 4-(Thiazol-5-Yl)-2-(Phenylamino)Pyrimidines are Highly Active Cdk9 Inhibitors: Synthesis, X-Ray Crystal Structure, Sar and Anti-Cancer Activities. Journal of Medicinal Chemistry. 56: 640. DOI: 10.2210/Pdb4Bcg/Pdb |
0.345 |
|
| 2013 |
Shao H, Foley D, Abbas AY, Hole AJ, Huang S, Shi S, Baumli S, Bradshaw TD, Noble M, Endicott JA, Pepper C, Wang S, Fischer PM. Abstract 697: Synthesis and biological evaluation of 2,4,5-substituted pyrimidines as highly selective CDK9 inhibitors for cancer treatment. Cancer Research. 73: 697-697. DOI: 10.1158/1538-7445.Am2013-697 |
0.396 |
|
| 2012 |
Boehringer J, Riedinger C, Paraskevopoulos K, Johnson EO, Lowe ED, Khoudian C, Smith D, Noble ME, Gordon C, Endicott JA. Structural and functional characterization of Rpn12 identifies residues required for Rpn10 proteasome incorporation. The Biochemical Journal. 448: 55-65. PMID 22906049 DOI: 10.1042/BJ20120542 |
0.306 |
|
| 2012 |
Endicott JA, Noble ME, Johnson LN. The structural basis for control of eukaryotic protein kinases. Annual Review of Biochemistry. 81: 587-613. PMID 22482904 DOI: 10.1146/Annurev-Biochem-052410-090317 |
0.615 |
|
| 2012 |
Baumli S, Hole AJ, Noble ME, Endicott JA. The CDK9 C-helix exhibits conformational plasticity that may explain the selectivity of CAN508. Acs Chemical Biology. 7: 811-6. PMID 22292676 DOI: 10.1021/cb2004516 |
0.31 |
|
| 2010 |
Echalier A, Endicott JA, Noble ME. Recent developments in cyclin-dependent kinase biochemical and structural studies. Biochimica Et Biophysica Acta. 1804: 511-9. PMID 19822225 DOI: 10.1016/j.bbapap.2009.10.002 |
0.357 |
|
| 2008 |
Lorenz S, Vakonakis I, Lowe ED, Campbell ID, Noble ME, Hoellerer MK. Structural analysis of the interactions between paxillin LD motifs and alpha-parvin. Structure (London, England : 1993). 16: 1521-31. PMID 18940607 DOI: 10.1016/J.Str.2008.08.007 |
0.609 |
|
| 2008 |
Sim E, Sandy J, Evangelopoulos D, Fullam E, Bhakta S, Westwood I, Krylova A, Lack N, Noble M. Arylamine N-acetyltransferases in mycobacteria. Current Drug Metabolism. 9: 510-9. PMID 18680471 DOI: 10.2174/138920008784892100 |
0.318 |
|
| 2008 |
Merckx A, Echalier A, Langford K, Sicard A, Langsley G, Joore J, Doerig C, Noble M, Endicott J. Structures of P. falciparum protein kinase 7 identify an activation motif and leads for inhibitor design. Structure (London, England : 1993). 16: 228-38. PMID 18275814 DOI: 10.1016/J.Str.2007.11.014 |
0.501 |
|
| 2007 |
Wang CJ, Hagemeier C, Rahman N, Lowe E, Noble M, Coughtrie M, Sim E, Westwood I. Molecular cloning, characterisation and ligand-bound structure of an azoreductase from Pseudomonas aeruginosa. Journal of Molecular Biology. 373: 1213-28. PMID 17904577 DOI: 10.1016/J.Jmb.2007.08.048 |
0.389 |
|
| 2007 |
Marchetti F, Sayle KL, Bentley J, Clegg W, Curtin NJ, Endicott JA, Golding BT, Griffin RJ, Haggerty K, Harrington RW, Mesguiche V, Newell DR, Noble ME, Parsons RJ, Pratt DJ, et al. Structure-based design of 2-arylamino-4-cyclohexylmethoxy-5-nitroso-6-aminopyrimidine inhibitors of cyclin-dependent kinase 2. Organic & Biomolecular Chemistry. 5: 1577-85. PMID 17571187 DOI: 10.1039/B703241B |
0.321 |
|
| 2007 |
Banerji S, Wright AJ, Noble M, Mahoney DJ, Campbell ID, Day AJ, Jackson DG. Structures of the Cd44-hyaluronan complex provide insight into a fundamental carbohydrate-protein interaction. Nature Structural & Molecular Biology. 14: 234-9. PMID 17293874 DOI: 10.1038/Nsmb1201 |
0.516 |
|
| 2007 |
Welburn JP, Tucker JA, Johnson T, Lindert L, Morgan M, Willis A, Noble ME, Endicott JA. How tyrosine 15 phosphorylation inhibits the activity of cyclin-dependent kinase 2-cyclin A. The Journal of Biological Chemistry. 282: 3173-81. PMID 17095507 DOI: 10.1074/jbc.M609151200 |
0.382 |
|
| 2007 |
Echalier A, Merckx A, Hole A, Endicott J, Noble M. New approaches in structure based kinase drug discovery Acta Crystallographica Section A. 63. DOI: 10.1107/S010876730709352X |
0.366 |
|
| 2006 |
Pratt DJ, Bentley J, Jewsbury P, Boyle FT, Endicott JA, Noble ME. Dissecting the determinants of cyclin-dependent kinase 2 and cyclin-dependent kinase 4 inhibitor selectivity. Journal of Medicinal Chemistry. 49: 5470-7. PMID 16942020 DOI: 10.1021/jm060216x |
0.363 |
|
| 2006 |
Cheng KY, Noble ME, Skamnaki V, Brown NR, Lowe ED, Kontogiannis L, Shen K, Cole PA, Siligardi G, Johnson LN. The role of the phospho-CDK2/cyclin A recruitment site in substrate recognition. The Journal of Biological Chemistry. 281: 23167-79. PMID 16707497 DOI: 10.1074/Jbc.M600480200 |
0.511 |
|
| 2006 |
Lowe ED, Hasan N, Trempe JF, Fonso L, Noble ME, Endicott JA, Johnson LN, Brown NR. Structures of the Dsk2 UBL and UBA domains and their complex. Acta Crystallographica. Section D, Biological Crystallography. 62: 177-88. PMID 16421449 DOI: 10.1107/S0907444905037777 |
0.491 |
|
| 2005 |
Noble M, Barrett P, Endicott J, Johnson L, McDonnell J, Robertson G, Zawaira A. Exploiting structural principles to design cyclin-dependent kinase inhibitors. Biochimica Et Biophysica Acta. 1754: 58-64. PMID 16361058 DOI: 10.1016/J.Bbapap.2005.08.019 |
0.597 |
|
| 2005 |
Trempe JF, Brown NR, Lowe ED, Gordon C, Campbell ID, Noble ME, Endicott JA. Mechanism of Lys48-linked polyubiquitin chain recognition by the Mud1 UBA domain. The Embo Journal. 24: 3178-89. PMID 16138082 DOI: 10.1038/Sj.Emboj.7600797 |
0.476 |
|
| 2005 |
Sandy J, Holton S, Fullam E, Sim E, Noble M. Binding of the anti-tubercular drug isoniazid to the arylamine N-acetyltransferase protein from Mycobacterium smegmatis. Protein Science : a Publication of the Protein Society. 14: 775-82. PMID 15722451 DOI: 10.1110/Ps.041163505 |
0.304 |
|
| 2005 |
Barrett CP, Noble ME. Molecular motions of human cyclin-dependent kinase 2. The Journal of Biological Chemistry. 280: 13993-4005. PMID 15695825 DOI: 10.1074/jbc.M407371200 |
0.336 |
|
| 2004 |
Pratt DJ, Endicott JA, Noble ME. The role of structure in kinase-targeted inhibitor design. Current Opinion in Drug Discovery & Development. 7: 428-36. PMID 15338952 |
0.369 |
|
| 2004 |
Noble ME, Endicott JA, Johnson LN. Protein kinase inhibitors: insights into drug design from structure. Science (New York, N.Y.). 303: 1800-5. PMID 15031492 DOI: 10.1126/Science.1095920 |
0.58 |
|
| 2004 |
Teriete P, Banerji S, Noble M, Blundell CD, Wright AJ, Pickford AR, Lowe E, Mahoney DJ, Tammi MI, Kahmann JD, Campbell ID, Day AJ, Jackson DG. Structure of the regulatory hyaluronan binding domain in the inflammatory leukocyte homing receptor CD44. Molecular Cell. 13: 483-96. PMID 14992719 DOI: 10.1016/S1097-2765(04)00080-2 |
0.501 |
|
| 2004 |
Wright A, Banerji S, Noble M, Jackson D, Campbell I, Day A. Analysis of CD44 hyaluronan-binding domain mutants by NMR International Journal of Experimental Pathology. 85: A77-A77. DOI: 10.1111/J.0959-9673.2004.390As.X |
0.483 |
|
| 2003 |
Holton S, Merckx A, Burgess D, Doerig C, Noble M, Endicott J. Structures of P. falciparum PfPK5 test the CDK regulation paradigm and suggest mechanisms of small molecule inhibition. Structure (London, England : 1993). 11: 1329-37. PMID 14604523 DOI: 10.1016/J.Str.2003.09.020 |
0.464 |
|
| 2003 |
Hoellerer MK, Noble ME, Labesse G, Campbell ID, Werner JM, Arold ST. Molecular recognition of paxillin LD motifs by the focal adhesion targeting domain. Structure (London, England : 1993). 11: 1207-17. PMID 14527389 DOI: 10.1016/J.Str.2003.08.010 |
0.513 |
|
| 2003 |
Sayle KL, Bentley J, Boyle FT, Calvert AH, Cheng Y, Curtin NJ, Endicott JA, Golding BT, Hardcastle IR, Jewsbury P, Mesguiche V, Newell DR, Noble ME, Parsons RJ, Pratt DJ, et al. Structure-based design of 2-arylamino-4-cyclohexylmethyl-5-nitroso-6-aminopyrimidine inhibitors of cyclin-dependent kinases 1 and 2. Bioorganic & Medicinal Chemistry Letters. 13: 3079-82. PMID 12941338 DOI: 10.1016/S0960-894X(03)00651-6 |
0.343 |
|
| 2003 |
Sim E, Pinter K, Mushtaq A, Upton A, Sandy J, Bhakta S, Noble M. Arylamine N-acetyltransferases: a pharmacogenomic approach to drug metabolism and endogenous function. Biochemical Society Transactions. 31: 615-9. PMID 12773167 DOI: 10.1042/Bst0310615 |
0.309 |
|
| 2003 |
Mettey Y, Gompel M, Thomas V, Garnier M, Leost M, Ceballos-Picot I, Noble M, Endicott J, Vierfond JM, Meijer L. Aloisines, a new family of CDK/GSK-3 inhibitors. SAR study, crystal structure in complex with CDK2, enzyme selectivity, and cellular effects. Journal of Medicinal Chemistry. 46: 222-36. PMID 12519061 DOI: 10.1021/Jm020319P |
0.47 |
|
| 2003 |
Kawamura A, Sandy J, Upton A, Noble M, Sim E. Structural investigation of mutant Mycobacterium smegmatis arylamine N-acetyltransferase: a model for a naturally occurring functional polymorphism in Mycobacterium tuberculosis arylamine N-acetyltransferase. Protein Expression and Purification. 27: 75-84. PMID 12509987 DOI: 10.1016/S1046-5928(02)00592-2 |
0.307 |
|
| 2003 |
Mesguiche V, Parsons RJ, Arris CE, Bentley J, Boyle FT, Curtin NJ, Davies TG, Endicott JA, Gibson AE, Golding BT, Griffin RJ, Jewsbury P, Johnson LN, Newell DR, Noble ME, et al. 4-Alkoxy-2,6-diaminopyrimidine derivatives: inhibitors of cyclin dependent kinases 1 and 2. Bioorganic & Medicinal Chemistry Letters. 13: 217-22. PMID 12482427 DOI: 10.1016/S0960-894X(02)00884-3 |
0.533 |
|
| 2002 |
Lowe ED, Tews I, Cheng KY, Brown NR, Gul S, Noble ME, Gamblin SJ, Johnson LN. Specificity determinants of recruitment peptides bound to phospho-CDK2/cyclin A. Biochemistry. 41: 15625-34. PMID 12501191 DOI: 10.1021/Bi0268910 |
0.537 |
|
| 2002 |
Davies TG, Bentley J, Arris CE, Boyle FT, Curtin NJ, Endicott JA, Gibson AE, Golding BT, Griffin RJ, Hardcastle IR, Jewsbury P, Johnson LN, Mesguiche V, Newell DR, Noble ME, et al. Structure-based design of a potent purine-based cyclin-dependent kinase inhibitor. Nature Structural Biology. 9: 745-9. PMID 12244298 DOI: 10.1038/Nsb842 |
0.55 |
|
| 2002 |
Davies TG, Pratt DJ, Endicott JA, Johnson LN, Noble ME. Structure-based design of cyclin-dependent kinase inhibitors. Pharmacology & Therapeutics. 93: 125-33. PMID 12191605 DOI: 10.1016/S0163-7258(02)00182-1 |
0.593 |
|
| 2002 |
Johnson LN, De Moliner E, Brown NR, Song H, Barford D, Endicott JA, Noble ME. Structural studies with inhibitors of the cell cycle regulatory kinase cyclin-dependent protein kinase 2. Pharmacology & Therapeutics. 93: 113-24. PMID 12191604 DOI: 10.1016/S0163-7258(02)00181-X |
0.608 |
|
| 2002 |
Gibson AE, Arris CE, Bentley J, Boyle FT, Curtin NJ, Davies TG, Endicott JA, Golding BT, Grant S, Griffin RJ, Jewsbury P, Johnson LN, Mesguiche V, Newell DR, Noble ME, et al. Probing the ATP ribose-binding domain of cyclin-dependent kinases 1 and 2 with O(6)-substituted guanine derivatives. Journal of Medicinal Chemistry. 45: 3381-93. PMID 12139449 DOI: 10.1021/Jm020056Z |
0.527 |
|
| 2002 |
Sandy J, Mushtaq A, Kawamura A, Sinclair J, Sim E, Noble M. The structure of arylamine N-acetyltransferase from Mycobacterium smegmatis--an enzyme which inactivates the anti-tubercular drug, isoniazid. Journal of Molecular Biology. 318: 1071-83. PMID 12054803 DOI: 10.1016/S0022-2836(02)00141-9 |
0.341 |
|
| 2002 |
Arold ST, Hoellerer MK, Noble ME. The structural basis of localization and signaling by the focal adhesion targeting domain. Structure (London, England : 1993). 10: 319-27. PMID 12005431 DOI: 10.1016/S0969-2126(02)00717-7 |
0.311 |
|
| 2002 |
Leng X, Noble M, Adams PD, Qin J, Harper JW. Reversal of growth suppression by p107 via direct phosphorylation by cyclin D1/cyclin-dependent kinase 4. Molecular and Cellular Biology. 22: 2242-54. PMID 11884610 DOI: 10.1128/Mcb.22.7.2242-2254.2002 |
0.415 |
|
| 2002 |
Noble M, Doerig C, Endicott J, Holton S, Roch KL, Meijer L, Merckx A. Plasmodium falciparumcyclin dependent kinases Acta Crystallographica Section A. 58. DOI: 10.1107/S0108767302093935 |
0.429 |
|
| 2001 |
Lawrie AM, Tito P, Hernandez H, Brown NR, Robinson CV, Endicott JA, Noble ME, Johnson LN. Xenopus phospho-CDK7/cyclin H expressed in baculoviral-infected insect cells. Protein Expression and Purification. 23: 252-60. PMID 11676600 DOI: 10.1006/Prep.2001.1504 |
0.559 |
|
| 2001 |
Song H, Hanlon N, Brown NR, Noble ME, Johnson LN, Barford D. Phosphoprotein-protein interactions revealed by the crystal structure of kinase-associated phosphatase in complex with phosphoCDK2. Molecular Cell. 7: 615-26. PMID 11463386 DOI: 10.1016/S1097-2765(01)00208-8 |
0.59 |
|
| 2001 |
Arold ST, Ulmer TS, Mulhern TD, Werner JM, Ladbury JE, Campbell ID, Noble ME. The role of the Src homology 3-Src homology 2 interface in the regulation of Src kinases. The Journal of Biological Chemistry. 276: 17199-205. PMID 11278857 DOI: 10.1074/Jbc.M011185200 |
0.576 |
|
| 2000 |
Arris CE, Boyle FT, Calvert AH, Curtin NJ, Endicott JA, Garman EF, Gibson AE, Golding BT, Grant S, Griffin RJ, Jewsbury P, Johnson LN, Lawrie AM, Newell DR, Noble ME, et al. Identification of novel purine and pyrimidine cyclin-dependent kinase inhibitors with distinct molecular interactions and tumor cell growth inhibition profiles. Journal of Medicinal Chemistry. 43: 2797-804. PMID 10956187 DOI: 10.1021/Jm990628O |
0.504 |
|
| 2000 |
Legraverend M, Tunnah P, Noble M, Ducrot P, Ludwig O, Grierson DS, Leost M, Meijer L, Endicott J. Cyclin-dependent kinase inhibition by new C-2 alkynylated purine derivatives and molecular structure of a CDK2-inhibitor complex. Journal of Medicinal Chemistry. 43: 1282-92. PMID 10753466 DOI: 10.1021/Jm9911130 |
0.383 |
|
| 2000 |
Noble M, Arold S, Brown N, Campbell I, Endicott JA, Gruber J, Johnson L, Ladbury J, Tucker J, Ulmer T. Molecular recognition in the action of protein kinases: the basis for affinity and specificity Acta Crystallographica Section a Foundations of Crystallography. 56: s102-s102. DOI: 10.1107/S010876730002273X |
0.664 |
|
| 1999 |
Endicott JA, Noble ME, Tucker JA. Cyclin-dependent kinases: inhibition and substrate recognition. Current Opinion in Structural Biology. 9: 738-44. PMID 10607671 DOI: 10.1016/S0959-440X(99)00038-X |
0.373 |
|
| 1999 |
Brown NR, Noble ME, Endicott JA, Johnson LN. The structural basis for specificity of substrate and recruitment peptides for cyclin-dependent kinases. Nature Cell Biology. 1: 438-43. PMID 10559988 DOI: 10.1038/15674 |
0.584 |
|
| 1999 |
Skamnaki VT, Owen DJ, Noble ME, Lowe ED, Lowe G, Oikonomakos NG, Johnson LN. Catalytic mechanism of phosphorylase kinase probed by mutational studies. Biochemistry. 38: 14718-30. PMID 10545198 DOI: 10.1021/Bi991454F |
0.56 |
|
| 1999 |
Noble ME, Endicott JA. Chemical inhibitors of cyclin-dependent kinases: insights into design from X-ray crystallographic studies. Pharmacology & Therapeutics. 82: 269-78. PMID 10454204 DOI: 10.1016/S0163-7258(98)00051-5 |
0.416 |
|
| 1999 |
Brown NR, Noble ME, Lawrie AM, Morris MC, Tunnah P, Divita G, Johnson LN, Endicott JA. Effects of phosphorylation of threonine 160 on cyclin-dependent kinase 2 structure and activity. The Journal of Biological Chemistry. 274: 8746-56. PMID 10085115 DOI: 10.1074/Jbc.274.13.8746 |
0.576 |
|
| 1999 |
Johnson LN, Noble MEM, Barford D, Brown N, Endicott JA, Lawrie A, Owen DJ. Signal Transduction Proteins: Structural Basis of Control by Phosphorylation Journal of Chemical Society of Pakistan. 21: 185-201. |
0.508 |
|
| 1998 |
Johnson LN, Lowe ED, Noble ME, Owen DJ. The Eleventh Datta Lecture. The structural basis for substrate recognition and control by protein kinases Febs Letters. 430: 1-11. PMID 9678585 DOI: 10.1016/S0014-5793(98)00606-1 |
0.579 |
|
| 1998 |
Endicott JA, Noble MEM. Structural principles in cell-cycle control: Beyond the CDKs Structure. 6: 535-541. PMID 9634691 |
0.302 |
|
| 1998 |
Gregoriou M, Noble ME, Watson KA, Garman EF, Krulle TM, de la Fuente C, Fleet GW, Oikonomakos NG, Johnson LN. The structure of a glycogen phosphorylase glucopyranose spirohydantoin complex at 1.8 A resolution and 100 K: the role of the water structure and its contribution to binding. Protein Science : a Publication of the Protein Society. 7: 915-27. PMID 9568898 DOI: 10.1002/Pro.5560070409 |
0.481 |
|
| 1998 |
Endicott J, Noble M, Lawrie A, Tunnah P, Brown N, Johnson L, Calvert A, Curtin N, Golding B, Griffin R, Newell. Insights into CDK inhibitor design from X-ray crystallographic studies Annals of Oncology. DOI: 10.1093/Annonc/9.Suppl_2.3 |
0.497 |
|
| 1998 |
Johnson LN, Lowe ED, Noble MEM, Owen DJ. The structural basis for substrate recognition and control by protein kinases Febs Letters. 430: 1-11. DOI: 10.1016/S0014-5793(98)00606-1 |
0.568 |
|
| 1997 |
Noble ME, Endicott JA, Brown NR, Johnson LN. The cyclin box fold: protein recognition in cell-cycle and transcription control. Trends in Biochemical Sciences. 22: 482-7. PMID 9433129 DOI: 10.1016/S0968-0004(97)01144-4 |
0.489 |
|
| 1997 |
Lowe ED, Noble MEM, Skamnaki VT, Oikonomakos NG, Owen DJ, Johnson LN. The crystal structure of a phosphorylase kinase peptide substrate complex: Kinase substrate recognition Embo Journal. 16: 6646-6658. PMID 9362479 DOI: 10.1093/Emboj/16.22.6646 |
0.548 |
|
| 1997 |
Johnson LN, Barford D, Owen DJ, Noble ME, Garman EF. From phosphorylase to phosphorylase kinase Advances in Second Messenger and Phosphoprotein Research. 31: 11-28. PMID 9344238 |
0.32 |
|
| 1997 |
Johnson LN, Brown NR, Endicoti JA, Lawrie AM, Löwe ED, Noble MEM, Tunnah P. The structural basis for control by phosphorylation Faseb Journal. 11: A1011. |
0.519 |
|
| 1996 |
Johnson LN, Noble MEM, Owen DJ. Active and inactive protein kinases: Structural basis for regulation Cell. 85: 149-158. PMID 8612268 DOI: 10.1016/S0092-8674(00)81092-2 |
0.574 |
|
| 1995 |
Endicott JA, Noble ME, Garman EF, Brown N, Rasmussen B, Nurse P, Johnson LN. The crystal structure of p13suc1, a p34cdc2-interacting cell cycle control protein Embo Journal. 14: 1004-1014. PMID 7889931 DOI: 10.1002/J.1460-2075.1995.Tb07081.X |
0.504 |
|
| 1995 |
Owen DJ, Papageorgiou AC, Garman EF, Noble MEM, Johnson LN. Expression, purification and crystallisation of phosphorylase kinase catalytic domain Journal of Molecular Biology. 246: 374-381. PMID 7877161 DOI: 10.1006/Jmbi.1994.0092 |
0.564 |
|
| 1995 |
Timms JF, Noble ME, Gregoriou M. An investigation of the role of Glu-842, Glu-844 and His-846 in the function of the cytoplasmic domain of the epidermal growth factor receptor. The Biochemical Journal. 308: 219-29. PMID 7755568 |
0.34 |
|
| 1993 |
Noble ME, Cleasby A, Johnson LN, Egmond MR, Frenken LG. The crystal structure of triacylglycerol lipase from Pseudomonas glumae reveals a partially redundant catalytic aspartate. Febs Letters. 331: 123-8. PMID 8405390 DOI: 10.1016/0014-5793(93)80310-Q |
0.485 |
|
| 1993 |
Noble MEM, Musacchio A, Saraste M, Courtneidge SA, Wierenga RK. Crystal structure of the SH3 domain in human Fyn; comparison of the three-dimensional structures of SH3 domains in tyrosine kinases and spectrin Embo Journal. 12: 2617-2624. PMID 7687536 DOI: 10.1002/J.1460-2075.1993.Tb05922.X |
0.336 |
|
| 1992 |
Musacchio A, Noble M, Pauptit R, Wierenga R, Saraste M. Crystal structure of a Src-homology 3 (SH3) domain Nature. 359: 851-855. PMID 1279434 DOI: 10.1038/359851A0 |
0.404 |
|
| Show low-probability matches. |